Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
As a world leading Chimeric Antigen Receptors (CARs) technique supplier, Creative Biolabs provides CellRapeutics™ fourth generation CARs design service. Our skilled scientists can construct the fourth generation CAR for treating solid tumors and liquid tumors in both preclinical and clinical studies.
Brentjens and Curran. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen Hematology Am Soc Hematol Educ Program. 2012;2012:143-51.
The promising results have been observed by reinfusion of CAR-T cells into different cancer patients, which have attracted more and more attention in clinical oncology area. However, there are still several flaws needed to be overcome before its large-scaled application in clinical trials, such as "on-target, off-tumor" toxicity, cytokines storm. Based on these, our seasoned researchers from Creative Biolabs design the fourth generation CAR to overcome these drawbacks.
In comparison with the previous three generations, our fourth generation CAR is engineered with an inducible expression component such as a cytokine (like IL-12). The CAR-modified T cell (called TRUCK T cell) can release this transgenic protein to regulate T-cell response. The advantage of CAR mediated TRUCK T cells is that cytokine (like IL-12) can increase the activation level of CAR-T cells and also activate innate immune cells to kill the antigen-negative cancer cells. Most importantly, this transgenic cytokine is stored in CAR-T cell and only obtained when it is induced. In addition, we also endue the fourth generation CAR a self-withdrawal mechanism, for instance caspase-9 gene as a suicide gene can be activated to rapidly withdraw CAR-T cells once the anti-tumor effect is achieved.
Creative Biolabs provides different generations of CAR construction services to satisfy your specific needs. Our excellent team is always here and ready to assist you. Please do not hesitate to contact us.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
